TABLE 1
Selection Characteristics of Compounds Chosen for the Determination of LC50 Using 3D Spheroids
| Compound | Metabolic cytochrome (references) | Terminal elimination half-life (h), (Schulz and Schmoldt, 2003) | Target tissue (at therapeutic dose) |
| APAP | 1A2, 2E1, and 3A4 (Hazai et al., 2002; Manyike et al., 2000) | 3 | CNS |
| Amiodarone | 3A4 (Zahno et al., 2011) | 75 | Cardiac cells |
| Diclofenac | 2C9 (Mancy et al., 1999) | 1.5 | Inflammatory cells |
| Metformin | 3A4 (Choi et al., 2010) | 3 | Liver |
| Phenformin | 1A1, 2D6 (Boobis et al., 1983; Granvil et al., 2002) | 7 | Liver |
| Valproic acid | 4B1 (Rettie et al., 1995) | 15 | CNS |
Note. CNS, central nervous system.